Literature DB >> 12020619

Ammonia and Alzheimer's disease.

Nikolaus Seiler1.   

Abstract

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder. Behavioural, cognitive and memory dysfunctions are characteristic symptoms of AD. The formation of amyloid plaques is currently considered as the key event of AD. Other histological hallmarks of the disease are the formation of fibrillary tangles, astrocytosis, and loss of certain neuronal systems in cortical areas of the brain. A great number of possible aetiologic and pathogenetic factors of AD have been published in the course of the last two decades. Among the toxic factors, which have been considered to contribute to the symptoms and progression of AD, ammonia deserves special interest for the following reasons: (a) Ammonia is formed in nearly all tissues and organs of the vertebrate organism; it is the most common endogenous neurotoxic compounds. Its effects on glutamatergic and GABAergic neuronal systems, the two prevailing neuronal systems of the cortical structures, are known for many years. (b) The impairment of ammonia detoxification invariably leads to severe pathology. Several symptoms and histologic aberrations of hepatic encephalopathy (HE), of which ammonia has been recognised as a pathogenetic factor, resemble those of AD. (c) The excessive formation of ammonia in the brains of AD patients has been demonstrated, and it has been shown that some AD patients exhibit elevated blood ammonia concentrations. (d) There is evidence for the involvement of aberrant lysosomal processing of beta-amyloid precursor protein (beta-APP) in the formation of amyloid deposits. Ammonia is the most important natural modulator of lysosomal protein processing. (e) Inflammatory processes and activation of microglia are widely believed to be implicated in the pathology of AD. Ammonia is able to affect the characteristic functions of microglia, such as endocytosis, and cytokine production. Based on these facts, an ammonia hypothesis of AD has first been suggested in 1993. In the present review old and new observations are discussed, which are in support of the notion that ammonia is a factor able to produce symptoms of AD and to affect the progression of the disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12020619     DOI: 10.1016/s0197-0186(02)00041-4

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  22 in total

1.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

2.  Senile portosystemic hepatic encephalopathy as a treatable dementia-like syndrome.

Authors:  Shoichi Ito; Ryuji Sakakibara; Yasumasa Yoshiyama; Takamichi Hattori
Journal:  J Neurol       Date:  2004-08       Impact factor: 4.849

Review 3.  Microglia.

Authors:  Denise van Rossum; Uwe-Karsten Hanisch
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

4.  Metabolism of galactose in the brain and liver of rats and its conversion into glutamate and other amino acids.

Authors:  Martin Roser; Djuro Josic; Maria Kontou; Kurt Mosetter; Peter Maurer; Werner Reutter
Journal:  J Neural Transm (Vienna)       Date:  2008-12-17       Impact factor: 3.575

5.  In Silico Preliminary Association of Ammonia Metabolism Genes GLS, CPS1, and GLUL with Risk of Alzheimer's Disease, Major Depressive Disorder, and Type 2 Diabetes.

Authors:  Jeddidiah W D Griffin; Ying Liu; Patrick C Bradshaw; Kesheng Wang
Journal:  J Mol Neurosci       Date:  2018-02-13       Impact factor: 3.444

6.  Is the urea cycle involved in Alzheimer's disease?

Authors:  Franck Hansmannel; Adeline Sillaire; M Ilyas Kamboh; Corinne Lendon; Florence Pasquier; Didier Hannequin; Geoffroy Laumet; Anais Mounier; Anne-Marie Ayral; Steven T DeKosky; Jean-Jacques Hauw; Claudine Berr; David Mann; Philippe Amouyel; Dominique Campion; Jean-Charles Lambert
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

7.  Methylamine, but not ammonia, is hypophagic in mouse by interaction with brain Kv1.6 channel subtype.

Authors:  Renato Pirisino; Carla Ghelardini; Alessandra Pacini; Nicoletta Galeotti; Laura Raimondi
Journal:  Br J Pharmacol       Date:  2004-04-20       Impact factor: 8.739

Review 8.  Hepatic consequences of vascular adhesion protein-1 expression.

Authors:  Chris J Weston; David H Adams
Journal:  J Neural Transm (Vienna)       Date:  2011-04-22       Impact factor: 3.575

9.  Glyphosate, pathways to modern diseases III: Manganese, neurological diseases, and associated pathologies.

Authors:  Anthony Samsel; Stephanie Seneff
Journal:  Surg Neurol Int       Date:  2015-03-24

10.  Metabolic states following accumulation of intracellular aggregates: implications for neurodegenerative diseases.

Authors:  Alexei Vazquez
Journal:  PLoS One       Date:  2013-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.